Lung cancer is the most commonly diagnosed malignancy and the leading cause of cancer-related mortality both in men and women worldwide.
The past few years have demonstrated great progress in the field of tumor immunotherapy through agents that address mechanisms of immune escape notably, so called immune checkpoint inhibitors (ICB). Indeed, ICB have emerged as a fatal weapon in the anticancer treatment arsenal. Anti-PD-1 and anti-PD-L1 antibodies have shown promising results in several cancers including Non-small Cell Lung Cancer (NSCLC) patients. Although such ICB extend patient's survival compared with conventional systemic therapies, they fail to control cancer progression in a significant proportion of patients which can reach up to 50-60% in NSCLC. Recent literature highlights a range of factors involved in the heterogeneous responses and failures to ICB therapies. The challenge is how can ICB treatment efficacy be extended to majority patients? To respond to this question, to increase the success of immunotherapy, immuno-oncology community develops combinations approaches.
The aim of these project is to evaluate the efficacy of Nivolumab plus a novel CD4Th1 inducer anti-cancer vaccine in NSCLC patients.
Nivolumab (NIVO), which is an anti-PD-1 antibody, has shown promising results in 2nd line treatment for advanced NSCLC.
UCPVax is a therapeutic anti-cancer vaccine based on the telomerase-derived helper peptides designed to induce strong TH1 CD4 T cell responses in cancer patients (NCT02818426).

Start Date09 Sep 2020

Sponsor / Collaborator

Centre Hospitalier Universitaire de Besancon

[+2]

NCT04280848 / Active, not recruitingPhase 2IIT

Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma

Glioblastoma (GBM) is the most frequent primary brain tumor and the brain tumor with the poorest prognosis. The current treatment relies on surgical resection of gross tumor followed by radiochemotherapy and adjuvant therapy with temozolomide.
After such therapy, most patients experiment recurrence and few therapeutic option are available. Despite such therapies, median survival only reaches around fifteen months.
There is a strong rational to develop telomerase vaccine in GBM. Telomerase (TERT) is a major oncogene, particularly in primary brain tumors 24. Alterations in TERT are very frequent in central nervous system tumors, seen most commonly in gliomas25. Mutations in the TERT promoter are found in approximately 80% of primary glioblastoma (GBM). These findings strongly support the rational to develop vaccine targeting telomerase in GBM.
The aim of this project is to evaluate UCPVax treatment in glioblastoma. UCPVax is a therapeutic anti-cancer vaccine based on the telomerase-derived helper peptides designed to induce strong TH1 CD4 T cell responses in cancer patients (NCT02818426).

Start Date26 May 2020

Sponsor / Collaborator

Centre Hospitalier Universitaire de Besancon

EUCTR2019-003805-82-FR / Unknown statusPhase 2

UCPVax plus Nivolumab versus standard chemotherapy as second line therapy in advanced non-small cell lung cancer : a randomized non-comparative phase II trial - Optim-UCPVax

Start Date05 Mar 2020

Sponsor / Collaborator

Chu De Besançon

100 Clinical Results associated with hTERT peptide-based vaccine(Invectys SA)

100 Translational Medicine associated with hTERT peptide-based vaccine(Invectys SA)

100 Patents (Medical) associated with hTERT peptide-based vaccine(Invectys SA)

Literatures (Medical) associated with hTERT peptide-based vaccine(Invectys SA)

01 May 2024·Archives of Microbiology

Peptide based vaccine designing against endemic causing mammarenavirus using reverse vaccinology approach

Article

Author: Giri, Kalyan ; Datta, Joyeeta ; Chaudhuri, Dwaipayan ; Majumder, Satyabrata

The rodent-borne Arenavirus in humans has led to the emergence of regional endemic situations and has deeply emerged into pandemic-causing viruses. Arenavirus have a bisegmented ambisense RNA that produces four proteins: glycoprotein, nucleocapsid, RdRp and Z protein. The peptide-based vaccine targets the glycoprotein of the virus encountered by the immune system. Screening of B-Cell and T-Cell epitopes was done based on their immunological properties like antigenicity, allergenicity, toxicity and anti-inflammatory properties were performed. Selected epitopes were then clustered and epitopes were stitched using linker sequences. The immunological and physico-chemical properties of the vaccine construct was checked and modelled structure was validated by a 2-step MD simulation. The thermostability of the vaccine was checked followed by the immune simulation to test the immunogenicity of the vaccine upon introduction into the body over the course of the next 100 days and codon optimization was performed. Finally a 443 amino acid long peptide vaccine was designed which could provide protection against several members of the mammarenavirus family in a variety of population worldwide as denoted by the epitope conservancy and population coverage analysis. This study of designing a peptide vaccine targeting the glycoprotein of mammarenavirues may help develop novel therapeutics in near future.

01 Jan 2024·International Immunopharmacology

Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model

Article

Author: Ibrahim, Eman I K ; Friberg, Lena E ; Ellingsen, Espen B ; Mangsbo, Sara M

Therapeutic cancer vaccines are novel immuno-therapeutics, aiming to improve clinical outcomes with other immunotherapies. However, obstacles to their successful clinical development remain, which model-informed drug development approaches may address. UV1 is a telomerase based therapeutic cancer vaccine candidate being investigated in phase I clinical trials for multiple indications. We developed a mechanism-based model structure, using a nonlinear mixed-effects modeling techniques, based on longitudinal tumor sizes (sum of the longest diameters, SLD), UV1-specific immunological assessment (stimulation index, SI) and overall survival (OS) data obtained from a UV1 phase I trial including non-small cell lung cancer (NSCLC) patients and a phase I/IIa trial including malignant melanoma (MM) patients. The final structure comprised a mechanistic tumor growth dynamics (TGD) model, a model describing the probability of observing a UV1-specific immune response (SI ≥ 3) and a time-to-event model for OS. The mechanistic TGD model accounted for the interplay between the vaccine peptides, immune system and tumor. The model-predicted UV1-specific effector CD4+ T cells induced tumor shrinkage with half-lives of 103 and 154 days in NSCLC and MM patients, respectively. The probability of observing a UV1-specific immune response was mainly driven by the model-predicted UV1-specific effector and memory CD4+ T cells. A high baseline SLD and a high relative increase from nadir were identified as main predictors for a reduced OS in NSCLC and MM patients, respectively. Our model predictions highlighted that additional maintenance doses, i.e. UV1 administration for longer periods, may result in more sustained tumor size shrinkage.

15 May 2023·International Journal of Cancer

Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long‐term clinical monitoring

Article

Author: Lilleby, Wolfgang ; Seierstad, Therese ; Inderberg, Else Marit ; Hole, Knut Håkon

AbstractProstate cancer is considered as poorly immunogenic. In a phase I/II study on de novo metastatic prostate cancer we found that a human telomerase reverse transcriptase (hTERT) vaccine induced an early immune response in most of the patients. Here we present the results from the long‐term monitoring of the immune responses and clinical outcomes. Twenty‐two men with ISUP 4 to 5 and lymph node and/or bone metastases were treated with androgen deprivation therapy (ADT), radiotherapy and the hTERT vaccine UV1 between January 2013 and July 2014. Immune response was monitored before, during and after vaccination and continued every 6 months until PSA progression. All patients had magnetic resonance imaging (MRI) at baseline, and after 6 months, 1 and 2 years, and at progression. The clinical outcome was time to progression, overall survival and prostate cancer‐specific survival. The median follow‐up was 62 months (range: 19‐101). At the last observation, nine of the 22 patients were still alive. Six have no progression, two have castration‐resistant disease treated with second‐line ADT and one has castration‐refractory disease. Median time to PSA progression was 21 months, median overall survival was 62 months and median prostate cancer‐specific survival was 84 months. Lack of immune response was an independent marker of prostate cancer death. The long‐term monitoring showed that some patients had unanticipated subsequent high immune responses without developing recurrence. This association indicates that there might be a clinical benefit of hTERT vaccination in a subgroup of men with primary metastatic hormone‐sensitive prostate cancer treated with ADT and radiotherapy.

News (Medical) associated with hTERT peptide-based vaccine(Invectys SA)

15 Jun 2023

·pipelinereview.com

Enterome's new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma

EO2463 uniquely targets four distinct B cell markers to maximize tumor killing and prevent immune escape, generating fast, strong and durable CD8+ T cell activation against malignant B cells Initial data from EONHL1-20/SIDNEY study presented at the 17th International Conference on Malignant Lymphoma (ICML) in Lugano Beneficial clinical responses observed following 6 weeks of treatment with EO2463 as monotherapy; preliminary complete response rate of 50% in evaluable patients for EO2463 in combination with lenalidomide + rituximab EO2463 is well tolerated as monotherapy, without additional safety signals when combined with lenalidomide + rituximab PARIS, France I June 14, 2023 I Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announces first clinical results from the Phase 1/2 (EONHL1-20/SIDNEY) trial of EO2463, an experimental treatment for indolent non-Hodgkin B cell lymphoma (iNHL). The initial data, presented at the 17 th International Conference on Malignant Lymphoma (ICML), show that EO2463, as monotherapy and in combination with the standard of care (lenalidomide and rituximab), is well tolerated and generates strong immune responses associated with early clinical activity. ICML is taking place June 13-17, 2023 in Lugano, Switzerland. EO2463 is an innovative, off-the-shelf immunotherapy candidate that combines four synthetic OncoMimic™ peptides. These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the B lymphocyte-specific lineage markers CD20, CD22, CD37 and CD268 (BAFF receptor). EO2463 also includes the helper peptide (CD4+ epitope) universal cancer peptide 2 (UCP2). The unique ability of EO2463 immunotherapy to selectively target multiple B cell markers enables the destruction of malignant B lymphocytes that are abundant in iNHL. By ensuring broad target coverage across malignant B cells while avoiding a detrimental impact on normal peripheral B cells, this novel approach aims to simultaneously improve safety and maximize efficacy, reducing the tumor cells’ capacity to develop immune-resistance mechanisms. Dr. Jan Fagerberg, Chief Medical Officer of Enterome said, “ EO2463 was designed to expand pre-existing memory cytotoxic T cells recognizing specific protein sequences from gut bacteria that cross-react with B cell specific proteins to drive targeted anti-tumor activity against B cell malignancies. We are very encouraged that EO2463 is showing promising efficacy with a good safety profile in indolent non-Hodgkin B cell lymphomas, confirming the validity of our approach and the ability of OncoMimics™ -based immunotherapies to target liquid tumors. We now look forward to continuing the trial with multiple expansion cohorts.” Key highlights from the EONHL1-20/SIDNEY trial poster presentation, entitled ‘ Phase 1 trial of EO2463 peptide-based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non-Hodgkin lymphoma ’ : Pierre Belichard, CEO of Enterome added, “ These very promising data from the SIDNEY trial as well as the positive data from our lead OncoMimics™ candidate, EO2401, being evaluated in recurrent glioblastoma and in adrenal tumors, continue to provide strong support for the potential of Enterome’s Mimicry platform to transform cancer immunotherapy, in particular its unique ability to enable a multi-targeting approach. This growing set of clinical data gives us confidence in our ability to generate OncoMimics™-based immunotherapies targeting unmet needs across a wide range of solid and liquid tumors. Alongside EO2401 and EO2463, we have initiated enrollment for a new clinical study to evaluate EO2040 in patients with colorectal cancer with ctDNA-defined, minimal residual disease. We are also preparing to enter another new OncoMimics™ candidate, EO4010, for the treatment of metastatic colorectal cancer, into clinical development.” The abstract #435 is available here and the presentation will be available on Enterome’s website . About OncoMimics™ OncoMimics™ immunotherapies are designed to activate pre-existing effector memory T cells that target bacterial (non-self) peptides, which are strongly cross-reactive against selected Tumor-Associated Antigens (TAAs), or B cell markers expressed on tumoral cells, resulting in a rapid targeted cytotoxic response against cancer. About EO2463 EO2463 is Enterome’s second, clinical-stage off-the-shelf OncoMimics™ peptide-based immunotherapy. It combines four microbial-derived OncoMimics™ peptides that closely mimic specific cytotoxic T cell (CD8+ T cell) epitopes in B cell Tumor-Associated Antigens CD20, CD22, CD37, and CD268 (BAFF receptor), as well as a helper CD4 peptide, UCP2. The EO2463 mimic peptides are non-self, high affinity and stable MHC class I binders. About SIDNEY SIDNEY (EONHL1-20/, NCT04669171) is a multicenter, open-label, non-randomized Phase 1/2 trial investigating EO2463 in monotherapy and in combination with standard of care - rituximab and rituximab in combination with lenalidomide – for treatment of patients with indolent Non-Hodgkin's Lymphoma. The trial is assessing safety, tolerability, immunogenicity and preliminary efficacy in 60 patients at centers in the US and Europe. Patient enrollment is ongoing. About iNHL Non-Hodgkin lymphoma is the seventh most common cause of new cancer cases among both men and women, accounting for 4% to 5% of new cancer cases, and 3% to 4% of cancer-related deaths. Indolent non-Hodgkin lymphoma (iNHL) constitutes a distinct subset where, even though currently available treatments are efficacious, the main disease subtypes, such as follicular lymphoma (FL) and marginal zone lymphoma (MZL), are considered non-curable in most patients. Thus, novel therapeutic approaches are still needed to enhance treatment outcomes and limit or delay the use of potentially more toxic therapies. About Enterome Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, allowing it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body. Its first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or actions of specific antigens, hormones, or cytokines. The company’s two pipelines of drug candidates include: Enterome employs 70 people and is headquartered in Paris, France. Since its inception, the company has raised a total of €116 million from Europe- and US-based life science investors and more than €100 million from pharmaceutical partnerships. For more information, please visit the company’s website at: www.enterome.com SOURCE: Enterome

ImmunotherapyPhase 1AACRClinical Study

14 Jun 2023

·www.biospace.com

Enterome's new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma

EO2463 uniquely targets four distinct B cell markers to maximize tumor killing and prevent immune escape, generating fast, strong and durable CD8+ T cell activation against malignant B cells Initial data from EONHL1-20/SIDNEY study presented at the 17th International Conference on Malignant Lymphoma (ICML) in Lugano Beneficial clinical responses observed following 6 weeks of treatment with EO2463 as monotherapy; preliminary complete response rate of 50% in evaluable patients for EO2463 in combination with lenalidomide + rituximab EO2463 is well tolerated as monotherapy, without additional safety signals when combined with lenalidomide + rituximab Paris, France – June14, 2023 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquidmalignanciesand inflammatory diseases based on its unique Mimicry platform, today announces first clinical results from the Phase 1/2 (EONHL1-20/SIDNEY) trial of EO2463, an experimental treatment for indolent non-Hodgkin B cell lymphoma (iNHL). The initial data, presented at the 17th International Conference on Malignant Lymphoma (ICML), show that EO2463, as monotherapy and in combination with the standard of care (lenalidomide and rituximab), is well tolerated and generates strong immune responses associated with early clinical activity. ICML is taking place June 13-17, 2023 in Lugano, Switzerland. EO2463 is an innovative, off-the-shelf immunotherapy candidate that combines four synthetic OncoMimic™ peptides. These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the B lymphocyte-specific lineage markers CD20, CD22, CD37 and CD268 (BAFF receptor). EO2463 also includes the helper peptide (CD4+ epitope) universal cancer peptide 2 (UCP2). The unique ability of EO2463 immunotherapy to selectively target multiple B cell markers enables the destruction of malignant B lymphocytes that are abundant in iNHL. By ensuring broad target coverage across malignant B cells while avoiding a detrimental impact on normal peripheral B cells, this novel approach aims to simultaneously improve safety and maximize efficacy, reducing the tumor cells’ capacity to develop immune-resistance mechanisms. Dr. Jan Fagerberg, Chief Medical Officer of Enterome said, “EO2463 was designed to expand pre-existing memory cytotoxic T cells recognizing specific protein sequences from gut bacteria that cross-react with B cell specific proteins to drive targeted anti-tumor activity against B cell malignancies.We are very encouraged that EO2463 is showing promising efficacy with a good safety pro indolent non-Hodgkin Bcell lymphomas, confirming the validity of ourapproach and the ability of OncoMimics™-based immunotherapies to target liquid tumors.We now look forward to continuing the trial with multiple expansion cohorts.” Key highlights from theEONHL1-20/SIDNEY trial poster presentation,entitled ‘Phase 1 trial of EO2463 peptide-based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non-Hodgkin lymphoma’: EO2463 appears well tolerated as a monotherapy, and without additional safety signals when combined with lenalidomide and rituximab. Clinical activity (metabolic marker/tumor size reduction) observed in 4 of 9 (44%) patients after 6 weeks on EO2463 monotherapy and encouraging preliminary complete response rate on EO2463 combination therapy (50% in patients evaluable after 19 weeks). Expansion of specific CD8+ T cells against the OncoMimic™ peptides and targeted B cell antigens was detected in 6 of 8 tested patients, including in 2 patients with no measurable B cells at baseline. EO2463 generated fast, strong, and durable on-target immune activation with cytotoxic T cells with the ability to kill malignant HLA-A2 B cell lines in vitro. Study on-going with opening of 3 extension cohorts: EO2463 monotherapy in patients with newly diagnosed, previously untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL), not in need of therapy ("watch-and-wait" setting) EO2463 + rituximab (from week 7) in patients with newly diagnosed, previously untreated, FL/MZL and low tumor burden, in need of therapy, and EO2463 + lenalidomide (from week 1) + rituximab (from week 19) in patients with relapsed/refractory, previously treated FL/MZL Pierre Belichard, CEO of Enterome added, “These very promising data from the SIDNEY trial as well as the positive data from our lead OncoMimics™ candidate, EO2401,being evaluated in recurrent glioblastoma and in adrenal tumors,continue to provide strong support for the potential of Enterome’s Mimicry platform to transform cancer immunotherapy, in particular its unique ability to enablea multi-targeting approach. This growing set of clinical datagives us confidence in our ability to generate OncoMimics™-based immunotherapies targeting unmet needs across a wide range of solid and liquid tumors. Alongside EO2401 and EO2463, we have initiated enrollmentfor a new clinical study to evaluate EO2040 in patients with colorectal cancer with ctDNA-defined, minimal residual disease. We are also preparing to enteranother new OncoMimics™ candidate, EO4010, for the treatment of metastatic colorectal cancer, into clinical development.” The abstract #435 is available here and the presentation will be available on Enterome’s website. *** Contacts ENTEROME MEDIA RELATIONS Guillaume Bayre Head of External Communications Tel; +33 (0)1 76 21 58 15 communication@enterome.com Sylvie Berrebi / Mark Swallow / David Dible MEDiSTRAVA Consulting Tel. +44 (0) 203 928 6900 enterome@medistrava.com About OncoMimics™ OncoMimics™ immunotherapies are designed to activate pre-existing effector memory T cells that target bacterial (non-self) peptides, which are strongly cross-reactive against selected Tumor-Associated Antigens (TAAs), or B cell markers expressed on tumoral cells, resulting in a rapid targeted cytotoxic response against cancer. About EO2463 EO2463 is Enterome’s second, clinical-stage off-the-shelf OncoMimics™ peptide-based immunotherapy. It combines four microbial-derived OncoMimics™ peptides that closely mimic specific cytotoxic T cell (CD8+ T cell) epitopes in B cell Tumor-Associated Antigens CD20, CD22, CD37, and CD268 (BAFF receptor), as well as a helper CD4 peptide, UCP2. The EO2463 mimic peptides are non-self, high affinity and stable MHC class I binders. About SIDNEY SIDNEY (EONHL1-20/, NCT04669171) is a multicenter, open-label, non-randomized Phase 1/2 trial investigating EO2463 in monotherapy and in combination with standard of care - rituximab and rituximab in combination with lenalidomide – for treatment of patients with indolent Non-Hodgkin's Lymphoma. The trial is assessing safety, tolerability, immunogenicity and preliminary efficacy in 60 patients at centers in the US and Europe. Patient enrollment is ongoing. About iNHL Non-Hodgkin lymphoma is the seventh most common cause of new cancer cases among both men and women, accounting for 4% to 5% of new cancer cases, and 3% to 4% of cancer-related deaths. Indolent non-Hodgkin lymphoma (iNHL) constitutes a distinct subset where, even though currently available treatments are efficacious, the main disease subtypes, such as follicular lymphoma (FL) and marginal zone lymphoma (MZL), are considered non-curable in most patients. Thus, novel therapeutic approaches are still needed to enhance treatment outcomes and limit or delay the use of potentially more toxic therapies. About Enterome Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, allowing it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body. Its first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or actions of specific antigens, hormones, or cytokines. The company’s two pipelines of drug candidates include: OncoMimics™ peptides, a pipeline of peptide-based immunotherapies. Lead candidate, EO2401, is in Phase 2 clinical trials in patients with glioblastoma and adrenal tumors and has demonstrated clinical proof of concept. EO2463 is in a Phase 1/2 clinical trial for indolent non-Hodgkin lymphomas, and has demonstrated a good safety pro first signs of efficacy. EO2040, a new immune therapy, is expected to start a Phase 2 trial in 2023 in patients suffering from colorectal cancer with ctDNA-defined, minimal residual disease. EO4010 is in development for third-line colorectal cancer and targeted to enter clinical trials in 2023. EndoMimics™ peptides, a pipeline of next generation bioactives acting like human hormones or cytokines, are being developed in collaboration with Nestlé Health Science, for food allergies and inflammatory bowel disease (IBD). Lead candidate, EB1010, expected to enter the clinic in 2024, is a potent local inducer of IL-10, designed to improve therapeutic outcomes for patients with IBD. Enterome employs 70 people and is headquartered in Paris, France. Since its inception, the company has raised a total of €116 million from Europe- and US-based life science investors and more than €100 million from pharmaceutical partnerships. For more information, please visit the company’s website at:

ImmunotherapyPhase 1Phase 2Clinical Result

100 Deals associated with hTERT peptide-based vaccine(Invectys SA)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glioblastoma	Phase 2	FR	Centre Hospitalier Universitaire de Besancon	26 May 2020
Non-Small Cell Lung Cancer	Phase 2	-	Invectys SAS	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03946358 (VolATIL, ESMO2024) Manual	Phase 2	Neoplasms HPV-related ctDNA	44	Atezolizumab+hTert-derived CD4 TH1 inducing vaccine	(wafsmuvrmh) = xdtgynzidu rdjydrerxc (sxarzucfcq ) View more	Positive	14 Sep 2024
NCT03946358 (VolATIL, ESMO2024) Manual	Phase 2	Neoplasms HPV-related ctDNA	44	Atezolizumab+hTert-derived CD4 TH1 inducing vaccine (HPV-related ctDNA detectable at baseline)	ybtxupsoqy(swigojfjpn) = biumdsdsgf inzqynjnss (anflvoathv )	Positive	14 Sep 2024
NCT04280848 (ASCO2023) Manual	Phase 2	Glioblastoma First line	31	UCPVax	vvgvmrsgpl(ishmpwwyis) = umwbtqwwkj qfxdzilsdg (iaqexheypl ) View more	Positive	26 May 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

hTERT peptide-based vaccine(Invectys SA)

Overview

Basic Info

Gene Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation